Search for content, post, videos

Hemab Therapeutics raises 135 million USD

Hemab Therapeutics has announced the closing of an oversubscribed Series B financing.

The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. All current investors including HealthCap, Novo Holdings, and RA Capital Management also invested.

Part of HealthCap’s VIII fund

Hemab Therapeutics has been a part of HealthCap’s VIII fund since 2021.


“Hemab is a great example of HealthCap’s goal of being a long-term investor on diseases with high unmet medical needs and breakthrough therapies where we can truly make a difference for patients,” says Dr. Mårten Steen, Managing Partner at HealthCap. “Hemab has made fantastic progress since we joined the company in 2021, and we look forward to continue working with the team.”

Support scientific and corporate growth plans through 2025

Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. The financing will support Hemab’s scientific and corporate growth plans through 2025, including completion of an ongoing Phase 1/2 clinical study of lead candidate HMB-001 in Glanzmann Thrombasthenia, initiation of studies, start and completion of Phase 1/2 clinical evaluation for HMB-VWF in von Willebrand disease, and future pipeline evolution in accordance with the company’s Hemab 1-2-5 strategic guidance—targeting development of 5 clinical assets by 2025, the company states.

“Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need,” said Benny Sorensen,  CEO & President of Hemab. “We’re grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation.”

Photo: iStock